BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 20, 2026
Breaking News: Best of BioWorld Science: Q2See today's BioWorld Science
Home » IL-17A as a new therapeutic target in glaucoma
To read the full story, subscribe or sign in.
Ocular

IL-17A as a new therapeutic target in glaucoma

June 1, 2023
It has been previously demonstrated that IL-17A plays a proinflammatory role in autoimmune diseases, and it has also been reported that IL-17A may take part in the occurrence and development of neurodegenerative disorders. Due to its association with both immunomodulation and inflammation, in a recent study, researchers from Shanghai Jiao Tong University aimed to investigate the role of IL-17A in the pathological process of glaucoma neuropathy.
BioWorld Science Ocular

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 17, 2026.
  • ALN-5288 lowers tau levels in preclinical models

    BioWorld Science
    Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
  • Elderly hands holding broken brain structure

    Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

    BioWorld Science
    Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
  • International currency symbols

    Capital remains selective in ‘barbell’ biotech market

    BioWorld
    Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
  • Brush scrubbing brain figurine with soap

    PSB-229 reduces plaque burden in Alzheimer’s models

    BioWorld Science
    Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing